ArticleTherapeutic advances in medical oncology2026
Historical evaluation of clinical outcomes and safety following isolated limb perfusion for unresectable melanoma: Real-world data from the Mannheim Cancer Center.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In-transit and bulky metastases of cutaneous melanoma represent a therapeutic challenge, particularly when lesions are not amenable to surgical excision. Modern systemic therapies have improved outcomes in advanced melanoma, but local disease progression often persists. Isolated limb perfusion (ILP) can serve as an effective regional salvage approach in patients with therapy-refractory local melanoma metastases when no other treatment options remain, offering the potential to achieve durable local control. Objectives: The objective of this study was to evaluate clinical responses, progression-free survival (PFS) and safety of ILP as a historical regional cytotoxic salvage therapy, and to exploratorily analyze clinical indicators associated with treatment response in patients with unresectable extremity melanoma metastases within a real-world setting. Design: This study was designed as a retrospective, exploratory, single-center observational cohort study. Methods: We performed a retrospective single-center analysis of 36 patients with unresectable in-transit or bulky melanoma metastases treated with ILP between 2005 and 2015. Clinical responses, local progression-free survival and safety were evaluated, and potential clinical correlates were exploratorily analyzed. Results: Overall, 72.2% of patients achieved local disease control, including a complete response (CR) rate of 27.8%. Patients with in-transit metastases had significantly longer PFS than those with bulky disease. Female sex, age >65 years, and BRAF mutation were associated with longer local PFS, although these findings should be interpreted cautiously due to small subgroup sizes. Prior systemic therapy did not significantly affect PFS, but patients previously treated with immunotherapy showed a trend toward shorter PFS. Treatment-related toxicity was limited to Wieberdink grade I-III reactions. Conclusions: ILP remains a valuable palliative salvage option for selected patients with melanoma metastases of the extremities who are refractory to modern systemic therapies. In this setting, ILP can achieve meaningful and durable local disease control with a manageable safety profile while preserving limb function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.